The Mitochondrion as an Emerging Therapeutic Target in Cancer
- 1 January 2020
- journal article
- review article
- Published by Elsevier BV in Trends in Molecular Medicine
- Vol. 26 (1), 119-134
- https://doi.org/10.1016/j.molmed.2019.06.009
Abstract
No abstract availableFunding Information
- National Cancer Institute (P30CA033572, U54CA209978, R01CA218545)
This publication has 142 references indexed in Scilit:
- Mitonuclear protein imbalance as a conserved longevity mechanismNature, 2013
- Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not AnticipateCancer Cell, 2012
- A Potent and Orally Active Antagonist (SM-406/AT-406) of Multiple Inhibitor of Apoptosis Proteins (IAPs) in Clinical Development for Cancer TreatmentJournal of Medicinal Chemistry, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent DioxygenasesCancer Cell, 2011
- Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activityThe Lancet Oncology, 2010
- Mitochondria and cell death: outer membrane permeabilization and beyondNature Reviews Molecular Cell Biology, 2010
- Cancer-associated IDH1 mutations produce 2-hydroxyglutarateNature, 2009
- Ure(k)a! Sirtuins Regulate MitochondriaCell, 2009
- Autocrine TNFα Signaling Renders Human Cancer Cells Susceptible to Smac-Mimetic-Induced ApoptosisCancer Cell, 2007